Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027

Cue Biopharma, Inc.

Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.
Net proceeds ~$8.9M (~$10.3M if underwriters exercise full option), after underwriting discounts and expenses.
Cash runway extended into Q1 2027 based on net proceeds, existing cash, and expected $10M from ImmunoScape collaboration.
Underwriters have 30-day option to purchase up to 5,357,140 additional shares and 2,678,570 warrants.

item 1.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cue Biopharma, Inc. entered into Underwriting Agreement with H.C. Wainwright & Co., LLC (effective 2025-12-19).

Action: entry
Agreement: underwriting
Counterparty: H.C. Wainwright & Co., LLC
Effective: 2025-12-19

Exact text from the filing

On December 19, 2025, Cue Biopharma, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC, as representative of the several underwriters named therein (collectively, the “Underwriters”), relating to an underwritten public offering

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Cue Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-326925

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.